[Post-Vaccination Adverse Events Related To The Administration Of The Covishield® Coronavirus Vaccine In Vaccinated Volunteers At The Bamako Dermatology Hospital From April To June 2021].
{"title":"[Post-Vaccination Adverse Events Related To The Administration Of The Covishield® Coronavirus Vaccine In Vaccinated Volunteers At The Bamako Dermatology Hospital From April To June 2021].","authors":"Oumar Coulibaly, Yaya Ibrahim Coulibaly, Mamadou Kodio, Mamadou Karim Touré, Abdoulaye Mamadou Traore, Mahamoud Mahamadou Koureichi, Kaman Dembélé, Mamadou Mady Keita, Oumar Traore, Korotoumou Traore, Kadiatou Diallo, Moussa Sangare, Diadje Tanapo, Abdoul Fatao Diabaté, Adama Aguissa Dicko, Claude Akakpo, Ousmane Faye","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to investigate adverse events related to the administration of Covishield vaccine from the AstraZeneca laboratory in volunteers vaccinated at the Dermatology Hospital of Bamako.</p><p><strong>Methodology: </strong>This was a Phase IV clinical trial involving volunteers vaccinated at the Dermatology Hospital of Bamako from April to June 2021. Scientific and ethical aspects were reviewed and addressed. The proposal for this study was approved by the scientific committee of the Hôpital de Dermatologie de Bamako.</p><p><strong>Results: </strong>A total of 1099 volunteers were included in the study. The median age of participants was 48 years (18-93 years) with a sex ratio of 1.81 (708/391). In all 90.2% of the 1219 adverse events were injection-site pain. Other adverse events were headache, tiredness, and muscle pain, with 3.2% (39/1219), 2.4% (29/1219) and 1.8% (22/1219) respectively. Only one case of diarrhea was reported, 0.08% (1/1219).</p><p><strong>Conclusion: </strong>Adverse events to this vaccine were mostly moderate and temporary but vary according to the population vaccinated individuals.</p>","PeriodicalId":74061,"journal":{"name":"Le Mali medical","volume":"39 3","pages":"45-51"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Le Mali medical","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The aim of this study was to investigate adverse events related to the administration of Covishield vaccine from the AstraZeneca laboratory in volunteers vaccinated at the Dermatology Hospital of Bamako.
Methodology: This was a Phase IV clinical trial involving volunteers vaccinated at the Dermatology Hospital of Bamako from April to June 2021. Scientific and ethical aspects were reviewed and addressed. The proposal for this study was approved by the scientific committee of the Hôpital de Dermatologie de Bamako.
Results: A total of 1099 volunteers were included in the study. The median age of participants was 48 years (18-93 years) with a sex ratio of 1.81 (708/391). In all 90.2% of the 1219 adverse events were injection-site pain. Other adverse events were headache, tiredness, and muscle pain, with 3.2% (39/1219), 2.4% (29/1219) and 1.8% (22/1219) respectively. Only one case of diarrhea was reported, 0.08% (1/1219).
Conclusion: Adverse events to this vaccine were mostly moderate and temporary but vary according to the population vaccinated individuals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
